ZNF32 and breast carcinoma: In vivo and in vitro experiments were conducted to confirm that ZNF32 histidine 179 and 183 single-site mutations (H179A, H183A) but not double-site mutation (H179, 183A) could promote the proliferation of breast cancer cells.